Key Insights

Highlights

Success Rate

85% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

6.7%

3 terminated out of 45 trials

Success Rate

85.0%

-1.6% vs benchmark

Late-Stage Pipeline

2%

1 trials in Phase 3/4

Results Transparency

41%

7 of 17 completed with results

Key Signals

7 with results85% success

Data Visualizations

Phase Distribution

41Total
Not Applicable (22)
Early P 1 (2)
P 1 (6)
P 2 (10)
P 3 (1)

Trial Status

Completed17
Recruiting11
Not Yet Recruiting8
Terminated3
Enrolling By Invitation2
Active Not Recruiting2

Trial Success Rate

85.0%

Benchmark: 86.6%

Based on 17 completed trials

Clinical Trials (45)

Showing 20 of 20 trials
NCT07849530Not ApplicableNot Yet RecruitingPrimary

Transcranial Magnetic Stimulation for Methamphetamine Use Disorder During Pregnancy

NCT06745128Phase 2Completed

Tirzepatide for Obesity and Meth Use Disorder

NCT06712446Not ApplicableCompletedPrimary

A Pilot Study of Transcranial Magnetic Stimulation Plus Episodic Future Thinking for Methamphetamine Use Disorder

NCT07825857Phase 2Not Yet RecruitingPrimary

Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder

NCT07774702Phase 2Not Yet RecruitingPrimary

Psilocybin for Methamphetamine Use Disorder

NCT06931197Not ApplicableWithdrawn

Implementing a Contingency Management Program Addressing Methamphetamine Use for and With the People of Hawai'i

NCT07399431Not ApplicableCompletedPrimary

Theta Burst Stimulation in the Management of Methamphetamine Use Disorder in Indonesia

NCT07121296Not ApplicableCompletedPrimary

Screen, Treat and Retain People With Primary Meth Use Disorder at MMT Clinics

NCT07459244RecruitingPrimary

ECG Findings in Methamphetamine Use

NCT07450027CompletedPrimary

LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis

NCT07213258Not ApplicableRecruiting

CHAMPION: Combining HIV And Meth Prevention and Treatment Interventions Optimized for HIV-Negative MSM

NCT07693608Phase 2Enrolling By Invitation

An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder

NCT07775807Not ApplicableNot Yet RecruitingPrimary

Closed-loop TBS Targeting rPO for the Core Clinical Features of the Methamphetamine Use Disorder

NCT07154160Not ApplicableNot Yet RecruitingPrimary

Closed-loop TMS for the Core Clinical Features of the Methamphetamine Use Disorder

NCT06538285Phase 2CompletedPrimary

Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

NCT07756736Phase 2Not Yet RecruitingPrimary

Psilocybin Therapy for Methamphetamine Use Disorder and HIV

NCT07509112Phase 2Not Yet RecruitingPrimary

Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

NCT06457230Not ApplicableRecruitingPrimary

Cerebellum-Prefrontal Paired-Pulse Stimulation for Methamphetamine Use Disorder

NCT06989853Early Phase 1RecruitingPrimary

Methamphetamine and Troriluzole

NCT07226596Not ApplicableRecruitingPrimary

Non-Abstinence Outcomes in Methamphetamine Use Disorder

Scroll to load more

Research Network

Activity Timeline